Everett, WA – January 22, 2010 – SNBL USA, one of the nation’s leading preclinical testing companies, is pleased to announce the appointment of Jeffery Engelhardt, DVM, PhD, DACVP, FIATP to the position of Director of Pathology.
"I am very pleased to have Dr. Engelhardt on board as an SNBL USA director. He brings tremendous expertise to SNBL USA’s anatomic and clinical pathology teams to ensure all of the varied facets meet client expectations and industry regulations and compliance," said Dr. Hideshi Tsusaki, SNBL USA president and COO. As Director of Pathology, Dr. Engelhardt is responsible for the overall operation, leadership, direction, and administration of SNBL USA's anatomic and clinical pathology laboratory teams.
Having most recently served as one of SNBL USA’s Senior Toxicological Pathologists, Dr. Engelhardt has significant experience and knowledge in the pathology field and is well-versed in many areas of pathology and the drug development industry including: Peer review and primary interpretation of gross, microscopic, and clinical pathology data from toxicology studies; Scientific review of general toxicology study reports and other documents submitted to regulatory agencies; Preparation of expert reports, specialized overviews, and integrated summaries of data derived from nonclinical drug safety studies, such as the CTD overview and summaries and IND overview; and Strategies for nonclinical development programs.
Prior to joining SNBL USA, Dr. Engelhardt has held various positions including President of Engelhardt Consulting, Inc., Executive Director, Toxicology at Amgen, Inc. and Pathology Research Advisor and Preclinical Expert at Eli Lilly and Company.
Dr. Engelhardt earned his BS degree from the University of Illinois and MS degree from the University of Notre Dame. After a period of time as a research associate in infectious diseases, he then went on to earn his DVM and PhD in Veterinary Pathology from Purdue University. As a board-certified diplomate by the American College of Veterinary Pathology, Dr. Engelhardt provides SNBL USA a very high level of expertise and experience that will significantly benefit SNBL USA and SNBL USA clients.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
